Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692383 | 0.91 | CA12 (0.34) | AKR1B1CA12CA1CA2CA7 | |
| SCHEMBL4893346 | 0.83 | LTA4H (0.45) | — | |
| SCHEMBL4889176 | 0.81 | CA12 (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4894660 | 0.79 | ABCG2 (0.33) | NQO2HTR6ABCG2 | |
| SCHEMBL4884401 | 0.78 | KDM4E (0.38) | AKR1B1CA12CA1CA2CA7 | |
| SCHEMBL4885813 | 0.75 | HTR6 (0.36) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3692384 | 0.75 | PPARG (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4893266 | 0.75 | NQO2 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4892292 | 0.74 | HTR6 (0.35) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4885808 | 0.74 | HSP90AA1 (0.38) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1401434-B1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | LILLY CO ELI (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
| EP-1401434-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002100403-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | PPARG, PPARA, PPARD | AKR1B1 181/4885CA12 4678/4885CA1 4785/4885 |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | PPARG, PPARA, PPARD | AKR1B1 181/4885CA12 4678/4885CA1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.